Clinical Trial Data Transparency in the EU: Is the New Clinical Trials Regulation a Game-Changer?

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Clinical Trial Data Transparency in the EU: Is the New Clinical Trials Regulation a Game-Changer? / Zemła-Pacud, Żaneta; Lenarczyk, Gabriela.

I: IIC International Review of Intellectual Property and Competition Law, Bind 54, Nr. 5, 2023, s. 732-763.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Zemła-Pacud, Ż & Lenarczyk, G 2023, 'Clinical Trial Data Transparency in the EU: Is the New Clinical Trials Regulation a Game-Changer?', IIC International Review of Intellectual Property and Competition Law, bind 54, nr. 5, s. 732-763. https://doi.org/10.1007/s40319-023-01329-4

APA

Zemła-Pacud, Ż., & Lenarczyk, G. (2023). Clinical Trial Data Transparency in the EU: Is the New Clinical Trials Regulation a Game-Changer? IIC International Review of Intellectual Property and Competition Law, 54(5), 732-763. https://doi.org/10.1007/s40319-023-01329-4

Vancouver

Zemła-Pacud Ż, Lenarczyk G. Clinical Trial Data Transparency in the EU: Is the New Clinical Trials Regulation a Game-Changer? IIC International Review of Intellectual Property and Competition Law. 2023;54(5):732-763. https://doi.org/10.1007/s40319-023-01329-4

Author

Zemła-Pacud, Żaneta ; Lenarczyk, Gabriela. / Clinical Trial Data Transparency in the EU: Is the New Clinical Trials Regulation a Game-Changer?. I: IIC International Review of Intellectual Property and Competition Law. 2023 ; Bind 54, Nr. 5. s. 732-763.

Bibtex

@article{919399803ef04508908849e29e954f9c,

title = "Clinical Trial Data Transparency in the EU: Is the New Clinical Trials Regulation a Game-Changer?",

abstract = "The benefits of access to clinical trial data are related to their inestimable value from the perspective of clinical trial participants, society as a whole, public health systems and scientific progress. In light of the development of innovative data analysis technologies, access to raw clinical trial data opens up an ever-widening array of possibilities: it can profoundly facilitate machine data analysis for, inter alia, hypothesis generation, risk modelling, counterfactual simulation and - finally - drug repurposing and development. The enactment of the new Clinical Trials Regulation (EU) No. 536/2014 (CTR) and introduction of the Clinical Trials Information System (CTIS) were heralded as ensuring a level of transparency in clinical trials that is sufficient to contribute to protecting public health and fostering the innovation capacity of European medical research, while recognizing the legitimate economic interests of sponsors. This paper presents the hitherto binding rules for the disclosure of clinical trial data and, against this background, their new framework, introduced by the CTR. In addition to assessing whether the CTR's objectives are fulfilled, this paper examines whether the latest changes impact the hitherto existing rules on protection of regulatory data via regulatory exclusivities. Finally, it points out concerns regarding whether data gathered in the CTIS can be efficiently used by innovative data analysis technologies for further processing for both commercial and non-commercial purposes. ",

author = "{\.Z}aneta Zem{\l}a-Pacud and Gabriela Lenarczyk",

note = "{\textcopyright} The Author(s) 2023.",

year = "2023",

doi = "10.1007/s40319-023-01329-4",

language = "English",

volume = "54",

pages = "732--763",

journal = "IIC International Review of Intellectual Property and Competition Law",

issn = "0018-9855",

publisher = "Verlag C.H./Beck oHG",

number = "5",